Early diagnostic value of serum GDF-15, RBP4 and SOCS3 in severe pneumonia with sepsis
Serum GDF-15, RBP4 and SOCS3 in severe pneumonia with sepsis
Abstract
Objective: To explore the early diagnostic value of the serum levels of growth differentiation factor 15 (GDF-15), retinol binding protein 4 (RBP4), and cytokine signal transduction inhibitory factor 3 (SOCS3) in patients with sepsis caused by severe pneumonia (SP).
Methods: A total of 110 SP patients admitted to our hospital from December 2023 to February 2025. Based on whether they acquired sepsis, the patients were split into two groups: 52 patients with sepsis and 58 patients without. Additionally, 114 healthy persons of the same age group who passed the health examination test in our hospital during the same period were selected as the control group. The levels of serum GDF-15, RBP4 and SOCS3 were detected via ELISA. Correlation analysis was conducted via the Pearson method. The factors influencing secondary sepsis in SP patients were examined using univariate and multivariate analysis. Serum GDF-15, RBP4, and SOCS3 levels were analyzed for diagnostic effectiveness using a receiver operating characteristic (ROC) curve. The regional differences in the ROC curves of the serum samples were analyzed via the paired comparison method.
Results: RBP4 levels were substantially lower (P<0.05) while serum GDF-15 and SOCS3 levels were significantly higher in the study group. Compared with those in nonseptic patients, Serum GDF-15 and SOCS3 levels were considerably higher in SP patients in the sepsis group, whereas the level of RBP4 was significantly lower (P<0.05). The sepsis group's APACHE II score was substantially higher than the nonsepsis group's (P<0.05). The APACHE II score showed a favorable correlation (P<0.05) with the levels of serum GDF-15 and SOCS3 in SP patients. The serum RBP4 level was negatively correlated with the APACHE II score (P<0.05). Elevated levels of serum GDF-15 and SOCS3 and increased APACHE II scores are risk factors for sepsis in SP patients, whereas elevated serum RBP4 levels are a protective factor for sepsis in SP patients (P<0.05). The area under the ROC curve (AUC) of the combined diagnosis of secondary sepsis in SP patients by serum GFF-15, RBP4 and SOCS3 levels was 0.946. The AUC of the combined diagnosis was superior to that of the individual diagnosis (Z=1.970, 3.898, 3.188; P<0.05).
Conclusion: Serum GDF-15, RBP4, and SOCS3 levels in SP patients fluctuate in tandem with the severity of the patient's illness and subsequent sepsis. The combined diagnosis of these three factors has certain value for secondary sepsis in SP patients.
References
2.Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M, Bos LD, Chalmers JD, Derde L, de Waele J, Garnacho-Montero J, Kollef M, Luna CM, Menendez R, Niederman MS, Ponomarev D, Restrepo MI, Rigau D, Schultz MJ, Weiss E, Welte T, Wunderink R. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023 Jun;49(6):615-632. doi: 10.1007/s00134-023-07033-8. Epub 2023 Apr 4. Erratum in: Intensive Care Med. 2023 Aug;49(8):1040-1041. doi: 10.1007/s00134-023-07082-z. PMID: 37012484; PMCID: PMC10069946.
3.Hwang W, Shimizu M, Lee JW. Role of extracellular vesicles in severe pneumonia and sepsis. Expert Opin Biol Ther. 2022 Jun;22(6):747-762. doi: 10.1080/14712598.2022.2066470. Epub 2022 Apr 16. PMID: 35418256; PMCID: PMC9971738.
4.Eriksson M, Lipcsey M, Ilboudo Y, Yoshiji S, Richards B, Hultström M. Uromodulin in sepsis and severe pneumonia: a two-sample Mendelian randomization study. Physiol Genomics. 2024 May 1;56(5):409-416. doi: 10.1152/physiolgenomics.00145.2023. Epub 2024 Feb 19. PMID: 38369967.
5.Liufu R, Chen Y, Wan XX, Liu RT, Jiang W, Wang C, Peng JM, Weng L, Du B. Sepsis-induced Coagulopathy: The Different Prognosis in Severe Pneumonia and Bacteremia Infection Patients. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231219249. doi: 10.1177/10760296231219249. PMID: 38126337; PMCID: PMC10748526.
6.Guzzardella A, Motos A, Vallverdú J, Torres A. Corticosteroids in sepsis and community-acquired pneumonia. Med Klin Intensivmed Notfmed. 2023 Dec;118(Suppl 2):86-92. English. doi: 10.1007/s00063-023-01093-w. Epub 2023 Dec 5. PMID: 38051381.
7.Henney AE, Riley DR, Hydes TJ, Anson M, Ibarburu GH, Frost F, Alam U, Cuthbertson DJ. Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data. Thorax. 2024 Dec 23;80(1):32-41. doi: 10.1136/thorax-2024-221906. PMID: 39645259; PMCID: PMC11671942.
8.Lu Y, Song L. Clinical Significance of Procalcitonin, Lactic Acid, and Endotoxin Testing for Children With Severe Pneumonia and Sepsis. Altern Ther Health Med. 2023 Apr;29(3):218-223. PMID: 36795523.
9.Chen Y, Zhou L, Wang J, Gu T, Li S. Clinical effect of Xuebijing combined with thymosinα1 on patients with severe pneumonia complicated with sepsis and its effect on serum inflammatory factors. Cell Mol Biol (Noisy-le-grand). 2022 Feb 27;67(6):228-235. doi: 10.14715/cmb/2021.67.6.30. PMID: 35818192.
10.Wang X, Wei C, He D, Huang D, Zhao Y, Ran L, Wang X, Yu H, Liang Z, Gong L. Incidence and risk factor of sepsis in patients with severe community-acquired pneumonia: a Chinese, single-center, retrospective study. BMC Infect Dis. 2025 May 2;25(1):649. doi: 10.1186/s12879-025-11027-w. PMID: 40316949; PMCID: PMC12048926.
11.Wu L, Li X, Yan J. Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma. Transl Oncol. 2024 Jul;45:101995. doi: 10.1016/j.tranon.2024.101995. Epub 2024 May 9. PMID: 38789241.
12.Zhang M, Zheng R, Liu WJ, Hou JL, Yang YL, Shang HC. Xuebijing injection, a Chinese patent medicine, against severe pneumonia: Current research progress and future perspectives. J Integr Med. 2023 Sep;21(5):413-422. doi: 10.1016/j.joim.2023.08.004. Epub 2023 Aug 11. PMID: 37652781.
13.Reijnders TDY, Laterre PF, François B, Sánchez García M, van Engelen TSR, Sie D, Scicluna BP, Ostanin DV, Galinsky KJ, Butler JM, Lombardo E, van der Poll T; SEPCELL study group. Effect of mesenchymal stem cells on the host response in severe community-acquired pneumonia. Thorax. 2024 Oct 16;79(11):1086-1090. doi: 10.1136/thorax-2024-222026. PMID: 39322407; PMCID: PMC11503173.
14.Wu L, Chen X, Zeng Q, Lai Z, Fan Z, Ruan X, Li X, Yan J. NR5A2 gene affects the overall survival of LUAD patients by regulating the activity of CSCs through SNP pathway by OCLR algorithm and immune score. Heliyon. 2024 Mar 28;10(7):e28282. doi: 10.1016/j.heliyon.2024.e28282. PMID: 38601554; PMCID: PMC11004709.
15.Brisca G, Buratti S, Basso L, Miano M, Salvati P, Castagnola E, Moscatelli A. Necrotizing pneumonia and severe COVID-19 in an infant with catheter-related bloodstream infection by methicillin-sensitive Staphylococcus aureus. Pediatr Int. 2023 Jan;65(1):e15401. doi: 10.1111/ped.15401. PMID: 36308020; PMCID: PMC9874413.
16.Xie M, Min Z, Jiang W, He Z, Xia X. Prognostic value of multivariate logistic regression analysis and amyloid A lactate monitoring in patients with severe pneumonia-associated sepsis. BMC Pulm Med. 2025 Apr 23;25(1):191. doi: 10.1186/s12890-025-03648-3. PMID: 40269823; PMCID: PMC12020197.
17.Guggemos J, Fuller SJ, Skarratt KK, Mayer B, Schneider EM. Loss-of-function/gain-of-function polymorphisms of the ATP sensitive P2X7R influence sepsis, septic shock, pneumonia, and survival outcomes. Front Immunol. 2024 Jun 20;15:1352789. doi: 10.3389/fimmu.2024.1352789. PMID: 38966639; PMCID: PMC11222724.
18.Razazi K, Luyt CE, Voiriot G, Rouzé A, Garnier M, Ferré A, Camous L, Heming N, Lapidus N, Charles-Nelson A, Mekontso-Dessap A; COVID-ICU Group on behalf of the REVA Network and the COVID-ICU Investigators. Ventilator-associated pneumonia related to extended-spectrum beta-lactamase producing Enterobacterales during severe acute respiratory syndrome coronavirus 2 infection: risk factors and prognosis. Crit Care. 2024 Apr 20;28(1):131. doi: 10.1186/s13054-024-04906-2. PMID: 38641851; PMCID: PMC11031867.
19.Bouras M, Rello J, Roquilly A. Steroids in severe community-acquired pneumonia: dangerous, worthless, or miracle cure? The roller coaster of clinical trials. Anaesth Crit Care Pain Med. 2023 Aug;42(4):101253. doi: 10.1016/j.accpm.2023.101253. Epub 2023 May 26. PMID: 37245688; PMCID: PMC10214762.
20.Wu L, Li X, Qian X, Wang S, Liu J, Yan J. Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity. Vaccines (Basel). 2024 Feb 12;12(2):186. doi: 10.3390/vaccines12020186. PMID: 38400169; PMCID: PMC10891594.
21.Souza CF, Borges LB, Oliveira FRMB, Silva PCS, Patricio DO, Rosales TO, Souza NF, Spiller F, Mansur DS, Assreuy J, Sordi R. Cannabinoid CB2receptor agonist reduces local and systemic inflammation associated with pneumonia-induced sepsis in mice. Eur J Pharmacol. 2023 Nov 15;959:176092. doi: 10.1016/j.ejphar.2023.176092. Epub 2023 Oct 4. PMID: 37797676.
22.Papadakis DD, Politou M, Kompoti M, Vagionas D, Kostakou E, Theodoulou D, Kaniaris E, Rovina N, Panayiotakopoulos G, Dimopoulos S, Koutsoukou A, Vasileiadis I. Immunostimulation and Coagulopathy in COVID-19 Compared to Patients With H1N1 Pneumonia or Bacterial Sepsis. In Vivo. 2022 Mar-Apr;36(2):954-960. doi: 10.21873/invivo.12786. PMID: 35241555; PMCID: PMC8931926.
23.Wu L, Li H, Liu Y, Fan Z, Xu J, Li N, Qian X, Lin Z, Li X, Yan J. Research progress of 3D-bioprinted functional pancreas and in vitro tumor models. International Journal of Bioprinting. 2024, 10(1), 1256. doi: 10.36922/ijb.1256.
24.Lei J, Wang L, Li Q, Gao L, Zhang J, Tan Y. Identification of RAGE and OSM as New Prognosis Biomarkers of Severe Pneumonia. Can Respir J. 2022 Jan 7;2022:3854191. doi: 10.1155/2022/3854191. PMID: 35035643; PMCID: PMC8759921.
25.Nakasone R, Ogi M, Kawamura A, Miyake O, Kido T, Abe S, Takahashi N, Nozu K, Fujioka K. Vertical Transmission of Coxsackievirus A6 with Severe Congenital Pneumonia/Sepsis. Int J Environ Res Public Health. 2023 Feb 6;20(4):2843. doi: 10.3390/ijerph20042843. PMID: 36833540; PMCID: PMC9957077.
26.Wu M, Zou ZY, Chen YH, Wang CL, Feng YW, Liu ZF. Severe COVID-19-associated sepsis is different from classical sepsis induced by pulmonary infection with carbapenem-resistant klebsiella pneumonia (CrKP). Chin J Traumatol. 2022 Jan;25(1):17-24. doi: 10.1016/j.cjtee.2021.11.001. Epub 2021 Nov 15. PMID: 34815141; PMCID: PMC8591816.
27.Moisa E, Dutu M, Corneci D, Grintescu IM, Negoita S. Hematological Parameters and Procalcitonin as Discriminants between Bacterial Pneumonia-Induced Sepsis and Viral Sepsis Secondary to COVID-19: A Retrospective Single-Center Analysis. Int J Mol Sci. 2023 Mar 7;24(6):5146. doi: 10.3390/ijms24065146. PMID: 36982221; PMCID: PMC10049727.
28.Chebet M, Mukunya D, Burgoine K, Kühl MJ, Wang D, Medina-Lara A, Faragher EB, Odiit A, Olupot-Olupot P, Stadskleiv Engebretsen IM, Waniaye JB, Wandabwa J, Tylleskär T, Weeks A. A cluster randomised trial to evaluate the effectiveness of household alcohol-based hand rub for the prevention of sepsis, diarrhoea, and pneumonia in Ugandan infants (the BabyGel trial): a study protocol. Trials. 2023 Apr 17;24(1):279. doi: 10.1186/s13063-023-07312-1. PMID: 37069595; PMCID: PMC10106319.
29.Kapoor A, Awasthi S, Kumar Yadav K. Predicting Mortality and Use of RISC Scoring System in Hospitalized Under-Five Children Due to WHO Defined Severe Community Acquired Pneumonia. J Trop Pediatr. 2022 Jun 6;68(4):fmac050. doi: 10.1093/tropej/fmac050. PMID: 35727140.
30.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959. doi: 10.1097/CAD.0000000000001319. Epub 2022 Aug 9. PMID: 35946526; PMCID: PMC9481295.
31.Liu X, Wang Z, Wu W, Zheng S. Sepsis and pneumonia caused by Enterococcus faecium following liver transplantation treated with contezolid as the first-line therapy. J Glob Antimicrob Resist. 2024 Sep;38:1-5. doi: 10.1016/j.jgar.2024.05.005. Epub 2024 May 21. PMID: 38777179.
32.Palma Medina LM, Babačić H, Dzidic M, Parke Å, Garcia M, Maleki KT, Unge C, Lourda M, Kvedaraite E, Chen P, Muvva JR, Cornillet M, Emgård J, Moll K; Karolinska K. I./K. COVID-19 Study Group; Michaëlsson J, Flodström-Tullberg M, Brighenti S, Buggert M, Mjösberg J, Malmberg KJ, Sandberg JK, Gredmark-Russ S, Rooyackers O, Svensson M, Chambers BJ, Eriksson LI, Pernemalm M, Björkström NK, Aleman S, Ljunggren HG, Klingström J, Strålin K, Norrby-Teglund A. Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia. Respir Res. 2023 Feb 24;24(1):62. doi: 10.1186/s12931-023-02364-y. PMID: 36829233; PMCID: PMC9950694.
33.Zhang L, Li X, Wang R. A fatal case of pneumonia and sepsis caused by sequence type 398 methicillin-susceptible Staphylococcus aureus carrying Pantone-Valentine leukocidin in China. J Infect Chemother. 2022 Sep;28(9):1329-1331. doi: 10.1016/j.jiac.2022.05.011. Epub 2022 May 30. PMID: 35654720.
34.Wang Y, Liang X, Jiang Y, Dong D, Zhang C, Song T, Chen M, You Y, Liu H, Ge M, Dai H, Xi F, Zhou W, Chen JQ, Wang Q, Chen Q, Yu W. Novel fast pathogen diagnosis method for severe pneumonia patients in the intensive care unit: randomized clinical trial. Elife. 2022 Oct 7;11:e79014. doi: 10.7554/eLife.79014. PMID: 36205312; PMCID: PMC9605691.
35.Luo H, Han W, Zhang J, Cheng W, Li D, Zhao M, Cui N, Zhu H. Effect of Improved Nursing Strategy on Prognosis of Immunosuppressed Patients With Pneumonia and Sepsis: A Prospective Cohort Study. J Intensive Care Med. 2024 Mar;39(3):257-267. doi: 10.1177/08850666231200184. Epub 2023 Sep 18. PMID: 37723966.
36.Asleh M, Feinstein Y, Lazar I, Rokney A, Baum M, Sagi O, Leibovitz E, Danino D. Severe Pneumonia Caused by Methicillin-Resistant Staphylococcus pseudintermedius in an Oncology Patient: Case Report and Literature Review. Microb Drug Resist. 2022 Feb;28(2):222-228. doi: 10.1089/mdr.2020.0469. Epub 2021 Oct 4. PMID: 34609906.
37.Yao H, Fu X, Xu Q, Li T, Li Y, Kang Y, Wu Q. The macrophages regulate intestinal motility dysfunction through the PGE2 Ptger3 axis during Klebsiella pneumonia sepsis. Front Immunol. 2023 Mar 29;14:1147674. doi: 10.3389/fimmu.2023.1147674. PMID: 37063880; PMCID: PMC10090685.
Copyright (c) 2025 Mingying Luo, Ziyi Wang, Zhener Ke, Cong Fu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.